about
sameAs
Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study.HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system.Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic reviewComparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample studyRisk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study.Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in DenmarkLong term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyIncidence of cervical cancer after several negative smear results by age 50: prospective observational study.Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays.Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.Primary HPV screening for cervical cancer prevention: results from European trials.Effects of streamlining cervical cancer screening the Dutch way: consequences of changes in the Dutch KOPAC-based follow-up protocol and consensus-based limitation of equivocal cytology.Human papillomavirus testing and genotyping in cervical screening.Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30: systematic review.Introduction of human papillomavirus vaccination in Nordic countries.The problem of false-positive human papillomavirus DNA tests in cervical screening.Immunosuppression and risk of cervical cancer.Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies.Trends of cervical cancer in Greenland: a 60-year overview.Cervical cancer screening at crossroads.Psychological effects of diagnosis and treatment of cervical intraepithelial neoplasia: a systematic review.Mortality of non-participants in cervical screening: Register-based cohort study.Challenges to cervical screening in a developing country: The case of Malaysia.Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review.Frequency of cervical intraepithelial neoplasia treatment in a well-screened population.The challenges of organising cervical screening programmes in the 15 old member states of the European Union.Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening.Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders.Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands.Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30years.Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark.Mothers' and their daughters' use of preventive measures against cervical cancer.Cervical cancer screening in the Faroe Islands.Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay.Non-participation in screening: the case of cervical cancer in Denmark.
P50
Q33647348-E0633AA5-FC50-460C-BDBA-4B970628FF50Q34006684-199D7944-A66A-4C15-BE15-2130C277467FQ34637954-F0668AEE-6840-4876-B4D3-B997350BA7C1Q34997580-CBA4B49B-F3C0-43E4-B236-96B86B233D90Q35342179-6F6F1CD7-227E-4744-A0F0-91823FFE73B3Q35898888-5DB2E395-F2F5-40D0-B32B-4BED632C630EQ36083187-79BD3D92-C099-4008-83A1-FD2995EFF20EQ36365581-A5573D04-B051-431A-8344-6F32A6563746Q36750670-40A2A380-2517-41B2-B015-D662BCF3B7D8Q37135912-F2DD9132-7FB4-4C9E-8231-240F94E27E27Q37169635-716EF278-7666-4AFB-ABD5-F02B0A31883CQ37363392-F56DFBA3-D747-491A-827F-C46FAC047A26Q37496183-9A049F1E-D580-43A9-909D-E7F4E7D7ABEFQ37630357-D1BE428A-CD06-495C-8EAA-B917E2057DB2Q37856220-37708A12-946D-46C6-B629-04BC23009550Q37909359-EA127E40-377E-4DA6-9C66-89DF2BD114CBQ37942021-820D6D58-C1F7-40BC-B250-E35AEF3D553EQ37966472-84226E44-343A-4306-9D68-14FBAE5C718DQ38046980-8FE0AEF5-5A3E-4317-8D88-C7D95DA127C5Q38069182-CE32D67E-691B-47A9-9225-6B8662E160EFQ38184467-9DAFDEBD-0183-4C08-A589-86AE65603FF9Q38186781-E877EBCD-2F2F-4913-AF5F-396260B37D06Q38232145-CE20F616-8573-4EBF-93AF-8442B095FDE3Q38290021-88EF8987-9B40-46B7-BD17-132D803BA633Q38423368-9CF96CBC-759E-4179-B5A3-416525B31458Q38431993-BD1D20D4-E681-444C-A9CC-BFA3E39CB206Q38755862-E6ADE335-09BC-4BE3-96FB-3AB2AE2DC571Q39736075-07F5BF1B-4374-4C42-B537-9A8E8A4972EDQ39953687-8D02B175-5D83-4719-A843-10AB1C57607DQ40043990-85C4B4C5-3510-487B-A663-C961A9C5DB25Q40116201-1B3E1482-1DA3-491C-9025-A338587C0F2BQ40305077-637B29ED-24A3-404F-972E-23FEDEE78E63Q40333905-130657C1-656D-4207-8E3E-339C21C23666Q40933987-381C7920-9E42-47CC-8977-341D997FA8A7Q41175427-A2EB7129-4884-4387-A9BF-26BD571991E4Q41286222-16ACF703-0059-436B-8C0E-81E538DABCCBQ41605883-FE66E3E3-E593-41E1-897A-833729A60105Q41633856-DC633AEB-F15D-4067-B912-1BC39BDB5CA0Q42285883-AD12B857-9403-4A9C-B069-FDF79F5CD7A3Q43408356-A6F6C2E8-0687-4479-A6D9-EA834FB762E1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Matejka Rebolj
@ast
Matejka Rebolj
@en
Matejka Rebolj
@es
Matejka Rebolj
@nl
type
label
Matejka Rebolj
@ast
Matejka Rebolj
@en
Matejka Rebolj
@es
Matejka Rebolj
@nl
prefLabel
Matejka Rebolj
@ast
Matejka Rebolj
@en
Matejka Rebolj
@es
Matejka Rebolj
@nl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0001-9597-645X
P734
P735
P7859
viaf-289192317